Literature DB >> 31088236

Re-education of macrophages as a therapeutic strategy in cancer.

Joanna Kowal1, Mara Kornete1, Johanna A Joyce1.   

Abstract

Tumor-associated macrophages (TAMs) can be educated within the tumor microenvironment to promote cancer development and progression. While TAM-targeted agents have largely focused on macrophage depletion as an anticancer strategy, it is becoming increasingly evident that TAM re-education may represent a more effective approach. In this perspective, we discuss different means to achieve TAM re-education, and review the beneficial effects of these strategies, particularly when combined with immune checkpoint inhibitors.

Entities:  

Keywords:  anticancer treatment; cancer immunotherapy; macrophages; tumor microenvironment; tumor-associated macrophages

Mesh:

Year:  2019        PMID: 31088236     DOI: 10.2217/imt-2018-0156

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  44 in total

1.  M2 polarization of tumor-associated macrophages is dependent on integrin β3 via peroxisome proliferator-activated receptor-γ up-regulation in breast cancer.

Authors:  Yuxin Shu; Menghao Qin; Yue Song; Qing Tang; Yahong Huang; Pingping Shen; Yan Lu
Journal:  Immunology       Date:  2020-04-29       Impact factor: 7.397

2.  Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy.

Authors:  Hisham Abdel-Azim; Hema Dave; Kimberly Jordan; Stephanie Rawlings-Rhea; Annie Luong; Ashley L Wilson
Journal:  Cytotherapy       Date:  2021-10-26       Impact factor: 5.414

3.  A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.

Authors:  Zuzana Tatarova; Dylan C Blumberg; James E Korkola; Laura M Heiser; John L Muschler; Pepper J Schedin; Sebastian W Ahn; Gordon B Mills; Lisa M Coussens; Oliver Jonas; Joe W Gray
Journal:  Nat Biotechnol       Date:  2022-07-04       Impact factor: 68.164

Review 4.  The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.

Authors:  Hiroyuki Takahashi; Gumpei Yoshimatsu; Denise Louise Faustman
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

Review 5.  Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils.

Authors:  Massimo Russo; Claudia Nastasi
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

6.  27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.

Authors:  Liqian Ma; Lawrence Wang; Adam T Nelson; Chaeyeon Han; Sisi He; Madeline A Henn; Karan Menon; Joy J Chen; Amy E Baek; Anna Vardanyan; Sayyed Hamed Shahoei; Sunghee Park; David J Shapiro; Som G Nanjappa; Erik R Nelson
Journal:  Cancer Lett       Date:  2020-08-28       Impact factor: 8.679

7.  Activating a collaborative innate-adaptive immune response to control metastasis.

Authors:  Lijuan Sun; Tim Kees; Ana Santos Almeida; Bodu Liu; Xue-Yan He; David Ng; Xiao Han; David L Spector; Iain A McNeish; Phyllis Gimotty; Sylvia Adams; Mikala Egeblad
Journal:  Cancer Cell       Date:  2021-09-02       Impact factor: 38.585

8.  Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B.

Authors:  Jiao Yin; Xiansheng Zhao; Xuejiao Chen; Guanxin Shen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 9.  Recent advances in the development of AHR antagonists in immuno-oncology.

Authors:  Lijun Sun
Journal:  RSC Med Chem       Date:  2021-04-06

Review 10.  Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.

Authors:  Seokhwan Chung; Richard A Revia; Miqin Zhang
Journal:  Nanoscale Horiz       Date:  2021-07-20       Impact factor: 11.684

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.